Supernus Pharmaceuticals (SUPN) PT Raised to $47 at Piper Sandler
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $44.04 -0.07%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Piper Sandler analyst David Amsellem raised the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $47.00 (from $40.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Nissan Chemical (4021:JP) PT Raised to JPY8,300 at Nomura/Instinet
- Medtronic, Inc. (MDT) PT Lowered to $101 at Needham
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
